For the quarter ending 2025-09-30, BIAF had $6,866,360 increase in cash & cash equivalents over the period. -$2,476,652 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -5,051,084 | -6,721,204 |
| Depreciation and amortization | 113,360 | 267,817 |
| Stock-based compensation expense | 67,132 | 538,223 |
| Fair value adjustment on warrants | 2,747,460 | 1,062,818 |
| Accounts and other receivables | 27,121 | -717,335 |
| Inventory | -8,737 | 16,363 |
| Prepaid expenses and other assets | 60,037 | -29,706 |
| Accounts payable | -229,076 | 182,526 |
| Accrued expenses | -63,487 | -350,688 |
| Unearned revenue | 13,511 | 0 |
| Operating lease right-of-use asset | -307 | -849 |
| Net cash used in operating activities | -2,480,298 | -4,288,981 |
| Proceeds from exercised stock options | - | 0 |
| Purchase of property and equipment | -3,646 | 64,213 |
| Proceeds from loans payable | - | 0 |
| Net cash used in investing activities | 3,646 | -64,213 |
| Proceeds from issuance of common stock from direct offering | 6,473,180 | 2,798,354 |
| Proceeds from exercise of warrants | 3,255,166 | 1,558,576 |
| Proceeds from issuance of convertible preferred stock | 990,000 | - |
| Payment of offering costs for financing activities | 1,418,459 | - |
| Payment on loans payable, net | -101,156 | 112,951 |
| Principal repayments on finance leases | 58,031 | 193,241 |
| Net cash provided by financing activities | 9,343,012 | 4,050,738 |
| Net increase (decrease) in cash and cash equivalents | 6,866,360 | -302,456 |
| Cash and cash equivalents at beginning of period | 1,105,291 | - |
| Cash and cash equivalents at end of period | 7,669,195 | - |
bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc. (BIAF)